Evidence map›Paper›PMID 30591049›Full record

ArticleJournal of experimental & clinical cancer research : CR2018

TNF-alpha and metalloproteases as key players in melanoma cells aggressiveness.

Stefania Rossi, Martina Cordella, Claudio Tabolacci, Giovanni Nassa, Daniela D'Arcangelo, Cinzia Senatore, Paolo Pagnotto, Roberta Magliozzi, Annamaria Salvati, Alessandro Weisz and 2 more

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 95 citations in OpenAlex.

  1. AC3Medical oncology (Northwood, London, England) · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Impact of Rab27 on Melanoma Cell Invasion and sEV Secretion.International journal of molecular sciences · 2024
    Article
  11. Network Analysis of miRNA and Cytokine Landscape in Human Hematopoiesis.International journal of molecular sciences · 2024
    Article
  12. Article
  13. Article
  14. Targeting inflammation as cancer therapy.Journal of hematology & oncology · 2024
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Stefania RossiDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, ISS, viale Regina Elena 299, 00161, Rome, Italy.
Martina CordellaDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, ISS, viale Regina Elena 299, 00161, Rome, Italy.
Claudio TabolacciDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, ISS, viale Regina Elena 299, 00161, Rome, Italy.
Giovanni NassaLaboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, Baronissi, SA, Italy.
Daniela D'ArcangeloLaboratory of Molecular Oncology, Istituto Dermopatico dell'Immacolata, IDI-IRCCS, Rome, Italy.
Cinzia SenatoreDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, ISS, viale Regina Elena 299, 00161, Rome, Italy.
Paolo PagnottoDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, ISS, viale Regina Elena 299, 00161, Rome, Italy.
Roberta MagliozziNeurology B, Department of Neurological and Movement Sciences, University of Verona, Verona, Italy.
Annamaria SalvatiLaboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, Baronissi, SA, Italy.
Alessandro WeiszLaboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, Baronissi, SA, Italy.
Antonio FacchianoLaboratory of Molecular Oncology, Istituto Dermopatico dell'Immacolata, IDI-IRCCS, Rome, Italy. a.facchiano@idi.it.
Francesco FacchianoDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, ISS, viale Regina Elena 299, 00161, Rome, Italy. francesco.facchiano@iss.it.
Istituto Superiore di Sanità · ITIstituto Dermopatico dell'Immacolata · ITUniversity of Salerno · ITGenomix Biotech (India) · INUniversity of Verona · IT

Funding

AIRC IG-17426Ministero della Salute Programma Italia-USA, Progetto Sieroproteomica; Progetto OncotecnologicoMinistero della Salute Ricerca CorrenteMIUR CNR Flagship Project InterOmicsUniversity of Salerno FARB 2017
6 · The paper itself

Abstract

backgroundMelanoma aggressiveness determines its growth and metastatic potential. This study aimed at identifying new molecular pathways controlling melanoma cell malignancy.

methodsTen metastatic melanoma cell lines were characterized by their proliferation, migration and invasion capabilities. The most representative cells were also characterized by spheroid formation assay, gene- and protein- expression profiling as well as cytokines secretion and the most relevant pathways identified through bioinformatic analysis were tested by in silico transcriptomic validation on datasets generated from biopsies specimens of melanoma patients. Further, matrix metalloproteases (MMPs) activity was tested by zymography assays and TNF-alpha role was validated by anti-TNF cell-treatment.

resultsAn aggressiveness score (here named Melanoma AGgressiveness Score: MAGS) was calculated by measuring proliferation, migration, invasion and cell-doubling time in10human melanoma cell lines which were clustered in two distinct groups, according to the corresponding MAGS. SK-MEL-28 and A375 cell lines were selected as representative models for the less and the most aggressive phenotype, respectively. Gene-expression and protein expression data were collected for SK-MEL-28 and A375 cells by Illumina-, multiplex x-MAP-and mass-spectrometry technology. The collected data were subjected to an integrated Ingenuity Pathway Analysis, which highlighted that cytokine/chemokine secretion, as well as Cell-To-Cell Signaling and Interaction functions as well as matrix metalloproteases activity were significantly different in these two cell types. The key role of these pathways was then confirmed by functional validation. TNF role was confirmed by exposing cells to the anti-TNF Infliximab antibody. Upon such treatment melanoma cells aggressiveness was strongly reduced. Metalloproteases activity was assayed, and their role was confirmed by comparing transcriptomic data from cutaneous melanoma patients (n = 45) and benign nevi (n = 18).

conclusionsInflammatory signals such as TNF and MMP-2 activity are key intrinsic players to determine melanoma cells aggressiveness suggesting new venue sin the identification of novel molecular targets with potential therapeutic relevance.

Indexed as

Cell Line, TumorCell ProliferationCytokinesHumansMelanomaMetalloproteasesProteomicsSkin NeoplasmsTumor Necrosis Factor-alphaCytokinesMetalloproteasesTumor Necrosis Factor-alphaCancerCutaneous melanomaCytokinesInflammationMalignancyMetalloproteasesProteomicsTNFUveal melanoma

Identifiers

PMID30591049
PMCPMC6309098
OpenAlexW2907033627

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.